-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Citius Oncology, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2023 to Q2 2025.
- Citius Oncology, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2025 was $264K, a 83.5% increase year-over-year.
- Citius Oncology, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2025 was $937K.
- Citius Oncology, Inc. annual Income Tax Expense (Benefit) for 2024 was $576K, unchanged from 2023.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)